These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 32807047)
81. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification. Li Y; Chu F; Li P; Johnson N; Li T; Wang Y; An R; Wu D; Chen J; Su Z; Gu X; Ding X J Ethnopharmacol; 2021 May; 271():113854. PubMed ID: 33513419 [TBL] [Abstract][Full Text] [Related]
82. Licorice: A Potential Herb in Overcoming SARS-CoV-2 Infections. Ng SL; Khaw KY; Ong YS; Goh HP; Kifli N; Teh SP; Ming LC; Kotra V; Goh BH J Evid Based Integr Med; 2021; 26():2515690X21996662. PubMed ID: 33787349 [TBL] [Abstract][Full Text] [Related]
83. Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites. Khan T; Khan MA; Mashwani ZU; Ullah N; Nadhman A Biocatal Agric Biotechnol; 2021 Jan; 31():101890. PubMed ID: 33520034 [TBL] [Abstract][Full Text] [Related]
84. Applications, phytochemistry, pharmacological effects, pharmacokinetics, toxicity of Song JW; Long JY; Xie L; Zhang LL; Xie QX; Chen HJ; Deng M; Li XF Chin Med; 2020; 15():102. PubMed ID: 32994803 [No Abstract] [Full Text] [Related]
85. Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease. van de Sand L; Bormann M; Alt M; Schipper L; Heilingloh CS; Steinmann E; Todt D; Dittmer U; Elsner C; Witzke O; Krawczyk A Viruses; 2021 Apr; 13(4):. PubMed ID: 33918301 [TBL] [Abstract][Full Text] [Related]
86. The pharmacological mechanism of Huashi Baidu Formula for the treatment of COVID-19 by combined network pharmacology and molecular docking. Cai Y; Zeng M; Chen YZ Ann Palliat Med; 2021 Apr; 10(4):3864-3895. PubMed ID: 33691446 [TBL] [Abstract][Full Text] [Related]
87. Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV-2 main protease. Hejazi II; Beg MA; Imam MA; Athar F; Islam A Food Chem Toxicol; 2021 Apr; 150():112057. PubMed ID: 33592201 [TBL] [Abstract][Full Text] [Related]
88. Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19). Al-Kamel H; Grundmann O Mini Rev Med Chem; 2021; 21(16):2204-2208. PubMed ID: 33568033 [TBL] [Abstract][Full Text] [Related]
89. COVID-19: the novel coronavirus disease and its manifestations and management in ophthalmology. Sun S; Su W; Lin CQ; Li X; Yan H; Tian B; Lin H Discov Med; 2020; 29(158):145-157. PubMed ID: 33007190 [TBL] [Abstract][Full Text] [Related]
90. The important herbal pair for the treatment of COVID-19 and its possible mechanisms. Xia S; Zhong Z; Gao B; Vong CT; Lin X; Cai J; Gao H; Chan G; Li C Chin Med; 2021 Mar; 16(1):25. PubMed ID: 33658066 [TBL] [Abstract][Full Text] [Related]
91. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. Zhang Q; Yue S; Wang W; Chen Y; Zhao C; Song Y; Yan D; Zhang L; Tang Y Am J Chin Med; 2021; 49(4):785-803. PubMed ID: 33853498 [TBL] [Abstract][Full Text] [Related]
92. Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms. He YQ; Zhou CC; Yu LY; Wang L; Deng JL; Tao YL; Zhang F; Chen WS Pharmacol Res; 2021 Jan; 163():105224. PubMed ID: 33007416 [TBL] [Abstract][Full Text] [Related]
93. Rhamnocitrin extracted from Nervilia fordii inhibited vascular endothelial activation via miR-185/STIM-1/SOCE/NFATc3. Lin T; Luo W; Li Z; Zhang L; Zheng X; Mai L; Yang W; Guan G; Su Z; Liu P; Li Z; Xie Y Phytomedicine; 2020 Dec; 79():153350. PubMed ID: 33002827 [TBL] [Abstract][Full Text] [Related]
94. Analysis of Chinese Herbal Formulae Recommended for COVID-19 in Different Schemes in China: A Data Mining Approach. Yin L; Gao Y; Li Z; Wang M; Chen K Comb Chem High Throughput Screen; 2021; 24(7):957-967. PubMed ID: 33001008 [TBL] [Abstract][Full Text] [Related]
95. [A single arm clinical study of 86 patients with common type of coronavirus disease 2019 treated by integrated traditional Chinese and Western medicine: multicenter case observation from 7 designated hospitals in Henan Province]. Xie Y; Wang J; Li S; Fu L; Sun J; Zhao J; Zhang H; Jia K; Zhao Q; Li B; Li J Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Aug; 32(8):922-927. PubMed ID: 32912403 [TBL] [Abstract][Full Text] [Related]
96. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322 [TBL] [Abstract][Full Text] [Related]
97. External treatment of traditional Chinese medicine for COVID-19: A protocol for systematic review and meta-analysis. Wu L; Yuan Q; Kuang Y; Chen Y; Li J; Feng Y; Luo J Medicine (Baltimore); 2020 Sep; 99(39):e22316. PubMed ID: 32991438 [TBL] [Abstract][Full Text] [Related]
98. The therapeutic efficacy of Chinese patent medicine combined with routine western medicine in the treatment of coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta-analysis. Zhang J; Li S; Zhao C; Wang W; Li F; Li F Medicine (Baltimore); 2020 Sep; 99(38):e22277. PubMed ID: 32957380 [TBL] [Abstract][Full Text] [Related]
99. Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases. Shu Z; Zhou Y; Chang K; Liu J; Min X; Zhang Q; Sun J; Xiong Y; Zou Q; Zheng Q; Ji J; Poon J; Liu B; Zhou X; Li X Front Med; 2020 Dec; 14(6):760-775. PubMed ID: 32926319 [TBL] [Abstract][Full Text] [Related]
100. Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. Chen X; Wu Y; Chen C; Gu Y; Zhu C; Wang S; Chen J; Zhang L; Lv L; Zhang G; Yuan Y; Chai Y; Zhu M; Wu C Acta Pharm Sin B; 2021 Jan; 11(1):222-236. PubMed ID: 33072499 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]